Novo Nordisk has introduced a new pharmacy service, NovoCare®, aimed at reducing the cost of its weight-loss drug Wegovy (semaglutide) to $499 per month for cash-paying patients. This price cut follows similar moves by competitors, including Eli Lilly, as the pharmaceutical industry experiences a price war over weight-loss medications. The company is positioning itself against both traditional pharmacies and competitors by offering direct access for consumers along with home delivery services. The new pricing strategy is meant to enhance accessibility for patients seeking effective obesity treatment.